Utility of CCR7 to differentiate classic Hodgkin lymphoma and other B-cell lymphomas by flow cytometry and immunohistochemistry
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqae119 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Xueyan Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, US. Hauptthemen laut MEDLINE: Receptors, CCR7, Hodgkin Disease, Biomarkers, Tumor, Lymphoma, B-Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objectives
Classic Hodgkin lymphoma (CHL) is characterized by infrequent neoplastic Hodgkin and Reed-Sternberg (HRS) cells in an inflammatory background. The diagnostic utility of CC-chemokine receptor 7 (CCR7) in CHL was explored using flow cytometry and immunohistochemistry (IHC).
Methods
Neoplastic specimens and non-neoplastic lymph nodes were immunophenotyped and CCR7 expression was measured semiquantitatively by flow cytometry (clone 3D12) and IHC (clone 150503).
Results
Our results showed that CCR7 was expressed on HRS cells in the vast majority of CHL cases (45/48 by flow cytometry, 57/59 by IHC) but rarely expressed in neoplastic cells in diffuse large B-cell lymphoma, not otherwise specified (1/25 by flow cytometry, 2/40 by IHC) and nodular lymphocyte predominant Hodgkin lymphoma (0/4 by flow cytometry, 1/13 by IHC). Primary mediastinal large B-cell lymphoma (PMLBCL) revealed weak CCR7 expression by flow cytometry in most cases (8/10) but only occasionally by IHC (2/12). Both cases (2/2) of T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) also showed CCR7 expression detected by flow cytometry compared with IHC (0/7). The HRS cells demonstrated a greater percentage of positive cells and greater antigen intensity than the other B-cell lymphomas by IHC. The expression identified by flow cytometry in PMLBCL and THRLBCL but not by IHC suggests that there may be differences in the detection capabilities of the 2 techniques or the 2 CCR7 clones used.
Conclusions
The expression of CCR7 in HRS cells suggests its potential utility in differentiating CHL from other B-cell lymphomas. Incorporating CCR7 into flow cytometry and IHC panels may further enhance the diagnostic sensitivity of CHL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, US.
- Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, US.
- Department of Pathology, City of Hope, Duarte, CA, US.
- Pathology Consultants, PC, Eugene/Springfield Lab, Springfield, OR, US.
ORCID-Profile: Kikkeri N Naresh
Zitieren
APA
Chen, X., Soma, L., Murphy, C., Tretiakova, M., Naresh, K. N., & Fromm, J. R. (2025). Utility of CCR7 to differentiate classic Hodgkin lymphoma and other B-cell lymphomas by flow cytometry and immunohistochemistry. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae119
Vancouver
Chen X, Soma L, Murphy C, Tretiakova M, Naresh KN, Fromm JR. Utility of CCR7 to differentiate classic Hodgkin lymphoma and other B-cell lymphomas by flow cytometry and immunohistochemistry. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae119
BibTeX
@article{Chen2025,
author = {Chen, Xueyan and Soma, Lori and Murphy, Claire and Tretiakova, Maria and Naresh, Kikkeri N and Fromm, Jonathan R},
title = {Utility of CCR7 to differentiate classic Hodgkin lymphoma and other B-cell lymphomas by flow cytometry and immunohistochemistry},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqae119}
}
EUVIMED